All entries for: Atossa Therapeutics, Inc.

March 25, 2026

Atossa Therapeutics, Inc.

Negative Outlook

Seattle, WA
1-50 employees

The taxes imposed by any new federal legislation and the expansion in government’s effect on the U.S. healthcare industry, including the Inflation Reduction Act enacted in August 2022, may result in decreased profits to us, lower reimbursements by payors for our products or reduced medical procedure volumes, all of which may adversely affect our business, financial condition and results of operations.

Disease Area: Oncology
Drug Type: Small Molecule
January 15, 2026

Atossa Therapeutics, Inc.

Orphan Drug Designation

Seattle, WA
1-50 employees

treatment of Duchenne muscular dystrophy

Disease Area: Rare Diseases
Scroll to Top